Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5070049 | 0.71 | LMNA (0.61) | LMNACYP2C19BLMSLC6A6KDM4E | |
| SCHEMBL23586729 | 0.64 | — | — | |
| SCHEMBL12064740 | 0.64 | LMNA (0.39) | LMNACYP2C19BLMSLC6A6APP | |
| SCHEMBL422082 | 0.64 | CYP1A2 (0.52) | LMNACYP2C19BLMAPPKDM4E | |
| Guanidine SCHEMBL11566422 | 0.64 | APP (0.44) | LMNACYP2C19BLMSLC6A6APP | |
| SCHEMBL27567157 | 0.64 | NOS3 (0.42) | LMNACYP2C19BLMSLC6A6APP | |
| SCHEMBL13863427 | 0.63 | LMNA (0.45) | LMNACYP2C19BLMSLC6A6APP | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL773704 | 0.63 | PTGS1 (0.45) | LMNACYP2C19BLMSLC6A6APP | |
| Guanidine SCHEMBL31456277 | 0.62 | LMNA (0.47) | LMNACYP2C19BLMSLC6A6APP | |
| SCHEMBL11133291 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084638-B2 | Sulfanyl derivatives and their use as synthesis intermediates | UCB PHARMA, S.A. (BE) | 2011-12-27 | — | — | US | claimed |
| EP-2173708-B1 | SULFANYL DERIVATIVES AND THEIR USE AS SYNTHESIS INTERMEDIATES | UCB PHARMA SA (BE) | 2011-03-09 | — | — | EP | claimed |
| US-20100292505-A1 | Sulfanyl Derivatives And Their Use As Synthesis Intermediates | UCB PHARMA, S.A. (BE) | 2010-11-18 | — | — | US | claimed |
| EP-2173708-A1 | SULFANYL DERIVATIVES AND THEIR USE AS SYNTHESIS INTERMEDIATES | UCB Pharma, S.A. (BE) | 2010-04-14 | — | — | EP | claimed |
| WO-2009019119-A1 | SULFANYL DERIVATIVES AND THEIR USE AS SYNTHESIS INTERMEDIATES | UCB PHARMA S.A. (BE) | 2009-02-12 | — | — | WO | claimed |
| US-8084638-B2 | Sulfanyl derivatives and their use as synthesis intermediates | UCB PHARMA, S.A. (BE) | 2011-12-27 | — | — | US | disclosed |
| EP-2173708-B1 | SULFANYL DERIVATIVES AND THEIR USE AS SYNTHESIS INTERMEDIATES | UCB PHARMA SA (BE) | 2011-03-09 | — | — | EP | disclosed |
| US-20100292505-A1 | Sulfanyl Derivatives And Their Use As Synthesis Intermediates | UCB PHARMA, S.A. (BE) | 2010-11-18 | — | — | US | disclosed |
| EP-2173708-A1 | SULFANYL DERIVATIVES AND THEIR USE AS SYNTHESIS INTERMEDIATES | UCB Pharma, S.A. (BE) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009019119-A1 | SULFANYL DERIVATIVES AND THEIR USE AS SYNTHESIS INTERMEDIATES | UCB PHARMA S.A. (BE) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292505-A1 | Sulfanyl Derivatives And Their Use As Synthesis Intermediates | CACNA1A, KCNN1, KCNN2 | LMNA 1481/4885CYP2C19 1509/4885BLM 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.